SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Healthcare >

Interpace Diagnostics Group Inc. (IDXG)

IDXG RSS Feed
Add IDXG Price Alert      Hide Sticky   Hide Intro
Moderator: OhManIDied, Joecanada13
Search This Board: 
Last Post: 8/22/2017 9:55:52 AM - Followers: 93 - Board type: Free - Posts Today: 2

 

NASDAQ CM | IDXG (Common Stock)

http://www.interpacediagnostics.com
http://pdi-inc.com

 

Corporate Headquarters
Interpace Diagnostics
Morris Corporate Center 1, Building A
300 Interpace Parkway
Parsippany, NJ 07054
844-405-9655

Share Structure:

Authorized Shares: 20,000,000 shares
Outstanding shares: 8,788,604 - May 05, 2017

Short interest:
64% of Float

Ownership:

Insiders:
John P. Dugan (Founder) : 4,869,878 common shares
other Insiders: Approx 2,672,149 shares collectively

Total Insider Ownership: 7,542,027 shares
Total Institutional Ownership: 30.6% 5.5 mil shares (6.5 Mil as of June 2017)

Investment Highlights:

Interpace Diagnostics (IDX) was formerly part of PDI that had both IDX and Commercial Services (CSO) businesses. PDI was renamed Interpace Diagnostics Group after the sale of CSO in December 2015
•Focused on developing and marketing molecular based diagnostic tests in high value precision pre-cancerous test markets
•Three proprietary cancer molecular tests on the market in GI and Endocrine
•PancraGenTM–The new standard of pancreatic cyst diagnostics
•ThyGenXTMand ThyraMIRTM-Next-Gen sequencing oncogene panel and miRNAclassifier in combination to improve risk classification of Thyroid nodules
•Two state of the art CLIA-certified labs
•Additional pipeline tests under development including BarreGenTMfor Barrett’s Esophagus, an esophageal cancer risk classifier
•Addressable potential market opportunity of $2.7 billion with all four tests
•Revenue of approximately $10 million in 2015, supported by IDX sales forces
•Focus for 2016: Grow recently launched ThyGenX/ThyraMIRtests and expand PancraGenmarket penetration

Key Milestones:
AUGUST2014:Acquired ThyroidAssetsfrom Asuragen
OCTOBER2014: Acquired RedPathInc., GI assetsand CLIA lab
DECEMBER2014: Launched ThyGenX™NextGen Sequencing Thyroid Cancer Test
FEBRUARY2015: Published landmark study on PancraGen™in Endoscopy
APRIL2015: Launched ThyraMIR™microRNA Gene Expression Thyroid Cancer Test
MAY2015: Published the major clinical validation study in JCEM for combining ThyGenXand ThyraMIRin a single testing service
MAY2015: Published BarreGen™BASE study on Barrett’s Esophagus cancer risk progression in AJG
AUGUST2015: Covered lives for Interpace Diagnostics products exceeded 100 million for all tests combined
OCTOBER2015: Data presented at ACG demonstrate that PancraGen™can improve detection of malignant or highly aggressive pancreatic cysts over current guidelines criteria, and improve patient outcomes in real life management decisions
New data presented at ATA further validates the power of combination testing by ThyGenX™and ThyraMIR™, improving the preoperative diagnosis of thyroid nodules with indeterminate cytology
DECEMBER2015: PDI transformed into Interpace Diagnostics Group through the sale of its CSO business to focus exclusively on molecular diagnostics


High Value Molecular Pre-Cancerous Test Market:
   


Management Team:

Jack Stover, Interim President and CEO

Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (“Zebec”) since April 2014.  Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013.  Mr. Stover has been a Director and Chairman of the Audit Committee of PDI, Inc., a public company since 2005. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins.  Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011.

From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange.  Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries.  Prior to that, Mr. Stover was executive vice president and director of a proprietary women’s pharmaceutical company, Gynetics, Inc. (“Gynetics”), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company.  For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the lifesciences industry division.  Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.

Greg Richard, SVP Commercial Services
Greg Richard, Sr. Vice President of PDI, Inc. and SVP of Commercial Services at Interpace Diagnostics, has been in the healthcare business for over 25 years in various industries including managed care, biotech pharmaceuticals, CRO services, and diagnostics. He started his career in sales at Aetna and moved to Genentech as the Director of Managed Care. He transitioned in to the diagnostics industry as the Vice President of Managed Care for Quest Diagnostics and served in this role for 8 years. Greg also led the international clinical trials sales team while at Quest. Following his tenure at Quest, Greg worked for several privately held companies including CRO’s, molecular diagnostics, and anatomic pathology services providers. He also served as the Sr. Vice President of Sales for the Northeast Division of LabCorp. Greg is a certified Six Sigma Green Belt and frequent speaker at healthcare industry conferences such as the G2 Lab Institute and the NextGen Dx Summit.

Syd Finkelstein, Chief Scientific Officer
Dr. Finkelstein is a board certified pathologist specializing in gastrointestinal pathology with extensive experience in molecular diagnostics. He is the Adjunct Professor of Pathology, Drexel University on the faculty of Allegheny General Hospital, Pittsburgh, PA. He serves as Adjunct Professor at Temple University.  He is the founder of RedPath Integrated Pathology, which was acquired by Interpace Diagnostics in 2014.  In this position, Dr. Finkelstein is applying clinical translational research of molecular genetic discoveries to standard surgical pathology practice a goal to which he has dedicated his entire career.   He spent 20 years as a practicing academic surgical pathologist, holding appointments as associate and then full professor at the University of Pittsburgh and at Hahnemann University in Philadelphia. In 1990, he began work on the development of Topographic Genotyping, his patented technology for enhancing polymerase chain reaction amplifiability of minute, microdissected, fixative treated tissue samples. Dr. Finkelstein is a nationally recognized expert in both Gastrointestinal Pathology and Solid Tissue Molecular Pathology.

https://www.doximity.com/pub/sydney-finkelstein-md?show_more=true#publications


James E. Early, Interim CFO 
Mr. Early, age 62, previously served as the Interim and subsequently permanent Chief Financial Officer of AbGenomics International Inc., a clinical stage drug development company with a product pipeline in immunology and oncology, from September 2015 to July 2016. Mr. Early also previously served as the Chief Financial Officer of Zebec Therapeutics, LLC from October 2014 to September 2015. In addition, Mr. Early has provided interim chief financial officer and business development services for pharmaceutical, life science and other similar companies as a sole proprietor from August 2009 to December 2013 and through Early Financial Consulting, LLC from January 2014 to the present. Mr. Early is a Certified Public Accountant and has an MBA in Finance and Accounting.

http://www.earlycfo.com/
Summary of Early's CFO services:

Strategic Planning
Deal Procurement and Contract Negotiations
Capitalization and Long-Term Financing
Private Equity Modeling
Insurance/Risk Management
IRC 409A and FAS 123R Share Payment/Stock Option Valuation Support
Acquisitions
Treasury Management
Internal Audits
 

Current Marketed Products:

BarreGen is a Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

Key Points:

While only about 0.5% of Barrett's esophagus patients will develop esophageal cancer, the 5-year survival rate of esophageal cancer ranges from 4% to 40%.

BarreGen utilizes an assay that assesses loss of heterozygosity and genetic mutations of multiple tumor-suppressor genes.

A longitudinal study shows the BarreGen test had an overall accuracy of 95% in identifying patients who progressed to cancer from those who did not.
 

http://www.ascopost.com/News/29620


PancraGEN® is a unique, DNA-based pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate, according to clinical studies, enabling effective risk stratification of patients.  Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.

Long-term follow-up outcomes data of patients (up to 8 years) from the National Pancreatic Cyst Registry supports PancraGEN’s ability to help accurately inform surgery and surveillance decisions of patients.

In a study of the National Pancreatic Cyst Registry, PancraGEN’s recommendation of surveillance was correct in 97% of patients. In fact, PancraGEN diagnoses were more beneficial to overall patient outcomes than sole reliance on International Consensus Guidelines (ICG) criteria.

PancraGEN has been performed on over 25,000 patients with pancreatic cysts, representing a full spectrum of pancreatic cyst patients with diverse clinical and molecular findings.

Medical Publications proving benefits of PancraGen:
http://www.interpacediagnostics.com/pancragen/publications/

ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer.  ThyGenX® and ThyraMIR™ combination testing helps to better assess the risk of thyroid nodules being either benign or malignant—and helps reduce unnecessary surgeries.
ThyGenX® is a highly specific oncogene (mutational) panel that assesses the most common genetic alterations across 8 genes associated with papillary carcinoma and follicular carcinoma.
ThyraMIR™ is the first and only miRNA gene expression classifier, and is based on evaluation of expression of 10 miRNAs.

Interpace Diagnostics' ThyGenX™ Thyroid Oncogene Panel molecular diagnostic test is used to improve surgical decision-making for patients with thyroid nodules when standard cytopathology does not provide a clear diagnosis of thyroid cancer. ThyGenX assists physicians in distinguishing between benign and malignant indeterminate thyroid nodules by utilizing state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid malignancies. The ThyGenX panel design is based on the miRInform® test, whose high predictive value has been validated in a recent prospective clinical study involving over 600 patients. Interpace Diagnostics acquired the miRInform test from Asuragen in 2014, and has now enhanced it by upgrading to a NGS platform which provides greater genomic insights and increased panel content.

Better than the competition:
"RE: our Thyroid products, customers continue to be receptive to our combined ThyGenX/ThyraMir assay and we are viewed positively vs. the other products in the market, including Afirma, ThyroSeq2, and Rosetta.  We will also be launching enhancements to our Thyroid offering in the next few weeks." Greg Richard (email 9-21-16)


 

AccuCEA™

AccuCEA is our highly accurate CEA method designed specifically for pancreatic cyst fluids and is especially convenient when used with PancraGEN.  Interpace currently performs over 6,000 AccuCEA tests per year for their customers.  CEA is a blood fluid chemistry test that is commonly done as part of an initial screening performed on patients suspected of having pancreatic and other types of cancer.

-The only CEA assay validated for use on small volumes (200uL) of cyst fluid.
-Delivers accurate CEA measurements on pancreatic cyst fluids
-Offers physicians more options – reserve cyst fluid for other diagnostic tests
-Results reported within 1-3 business days

New Version of AccuCEA™ Called "Insights" Provides Physicians Access to 15,000 Patient Database:

The new AccuCEA Insights service provides physicians for whom the Company has already provided first line testing, with additional information on how those results compare to those of other patients in the Company's proprietary database of over 15,000 patients, thus reporting incremental and valuable information on the patient's potential molecular profile and overall risk for developing pancreatic cancer. When the report is delivered to the ordering physician, they have an opportunity to speak with one of the Company's expert molecular pathologists and discuss the potential benefits of conducting a full, molecular pathology review using PancraGen®, the Company's fully integrated product that considers all the results from first line testing, imaging, cytology, and molecular testing and stratifies the patient in one of 4 risk categories.

Events/Presentations:

86th Annual Meeting of the American Thyroid Association (ATA) in Denver, Colorado

The first of the two posters entitled "Molecular Analysis of Thyroid Malignancy Using Cytology Smears by Combined THYGENX™ and THYRAMIR™ testing: A Prospective Study" highlights the clinical performance of the combined ThyGenX + ThyraMIR tests when carried out on Fine Needle Aspirate (FNA) material smeared on cytology slides.  

The second poster entitled "The Majority of Non-Diagnostic (Insufficient) Thyroid Nodule Cytology Samples Can Effectively Undergo Molecular (Combined Mutational and MicroRNA Classifier) Analysis Using a Needle Aspiration Approach" demonstrates that Interpace's scientists were able to perform molecular analysis in cases where cytology results were insufficient. 

Set for presentation of posters 50 and 51 on Sept 23:
http://online.liebertpub.com/doi/full/10.1089/thy.2016.29027.abstracts

"DNA Analysis of Pancreatic Cystic Lesions Has Value in Assessing Risk of Future Malignancy"
Oct 19, presented by:

James J. Farrell, MD, Sara Jackson, PhD, Nicole Toney, MPH,
Tamas Gonda, MD, Yale University School of Medicine, New
Haven, CT, Interpace Diagnostics Corporation, Pittsburgh, PA,
New York-Presbyterian/Columbia University Medical Center, New
York, NY

"We are attending the ACG mtg. in Oct. in Las Vegas, where data on our PancraGen test is being presented in a podium presentation by Dr. James Farrell of Yale. " Greg Richard (email 9-21-16)

Preliminary Program (refer to page 41 of pdf)
http://acgmeetings.gi.org/pdfs/ACG16-Preliminary-Program.pdf


Lab Locations
 

 
IDXG
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDXG News: Revised Proxy Soliciting Materials (definitive) (defr14a) 08/16/2017 02:46:42 PM
IDXG News: Interpace Diagnostics Announces Coverage of Thyroid Test by Oxford Health Plans 08/16/2017 08:30:00 AM
IDXG News: Proxy Statement (definitive) (def 14a) 08/14/2017 09:01:56 AM
IDXG News: Current Report Filing (8-k) 08/10/2017 10:01:38 AM
IDXG News: Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results, Business Progress and Recent Accomplishments 08/10/2017 09:51:10 AM
PostSubject
#2556   It was looking a lot better at 1.48 drlord10 08/22/17 09:55:51 AM
#2555   Looking good europtiger 08/22/17 09:39:16 AM
#2554   IDXG 1.31 RED GREEN SIGNAL PAC 08/21/17 01:25:03 PM
#2553   IDXG 1.17 third day down in low volume. PAC 08/21/17 11:57:52 AM
#2552   What is going on with the market today. drlord10 08/21/17 10:41:37 AM
#2551   this insurance coverage means a strong 3rd quarter Camelot 08/19/17 09:00:44 PM
#2550   Locked and loaded here. I think it will start Camelot 08/19/17 07:19:38 PM
#2549   Thanks Bizman. I bought in for the following MUZZGUY 08/19/17 04:54:45 PM
#2548   More insurance coverage, partnership (which would send us Bizman2 08/19/17 02:37:57 PM
#2547   What news can be forthcoming that will increase MUZZGUY 08/18/17 05:09:27 PM
#2546   Looking very solid. Camelot 08/18/17 02:40:53 PM
#2545   lol...people have been saying that for about 8 rpablo23 08/18/17 01:42:37 PM
#2544   They can't short this forever. At some point short Camelot 08/18/17 01:17:04 PM
#2543   I think so. Solid support at the current levels. Next Camelot 08/18/17 01:06:46 PM
#2542   IDXG 1.24 like the setup for next leg up PAC 08/18/17 12:19:24 PM
#2541   Locked and loaded here and adding more. This is Camelot 08/18/17 12:13:17 PM
#2540   "I think it has support at 1.25 to jrf30 08/18/17 09:54:37 AM
#2539   no question about it. Camelot 08/18/17 09:13:25 AM
#2538   How do you plan to add on Saturday, OhManIDied 08/18/17 06:28:49 AM
#2537   for the record stock has 8.71% institutional ownership. Camelot 08/17/17 10:00:11 PM
#2536   float is just 8.77 million. Camelot 08/17/17 09:18:35 PM
#2535   I think it has support at 1.25 to Camelot 08/17/17 09:04:12 PM
#2534   Sadly (for us retail) that's exactly how it modrica 08/17/17 04:41:32 PM
#2533   This is from post #2384 rpablo23 08/17/17 04:04:31 PM
#2532   Pretty simple. IDXG needed funding and they rpablo23 08/17/17 03:59:26 PM
#2531   Maxim Group initiated the coverage yesterday. They gave it Camelot 08/17/17 03:03:02 PM
#2530   $IDXG Why would a Huge Investment firm be invested matticus22 08/17/17 02:53:57 PM
#2529   I mean if you look into what they've rpablo23 08/17/17 02:45:13 PM
#2528   $IDXG Power hour should bring us to the 1.40's matticus22 08/17/17 02:13:58 PM
#2527   On to your next pump after dumping inmg TheDeacon00 08/17/17 01:21:52 PM
#2526   Lock up your shares and then add more. Do Camelot 08/17/17 01:06:35 PM
#2525   Looking for a $1.75 close today. $2 or more Camelot 08/17/17 12:39:57 PM
#2524   Looks good even after the blatant manipulation. It won't Camelot 08/17/17 12:26:16 PM
#2523   What makes you different? Bizman2 08/17/17 12:01:01 PM
#2522   $IDXG Someone has a motive and being aggressive shows matticus22 08/17/17 12:00:38 PM
#2521   Please don't listen to these two idiots. rpablo23 08/17/17 11:49:25 AM
#2520   $IDXG Looking good here after the shake down. Bullish recovery matticus22 08/17/17 11:12:08 AM
#2519   load the hell out of the minor dips. Camelot 08/17/17 10:46:50 AM
#2518   Climb is resumed. Short squeeze here is going to Camelot 08/17/17 10:27:35 AM
#2517   Agreed. I have added more several times. This dip is Camelot 08/17/17 10:25:37 AM
#2516   Is time to load kraken17 08/17/17 09:39:03 AM
#2515   This is absolutely huge for idxg. Stock is going Camelot 08/16/17 11:53:28 PM
#2514   Very insightful. Please pump more rpablo23 08/16/17 11:40:56 PM
#2513   $IDXG https://cnafinance.com/interpace-diagnostics-group-idxg-stock-gaining-on- matticus22 08/16/17 11:27:13 PM
#2512   $IDXG https://www.wsj.com/articles/PR-CO-20170816-905524 $ ~ $ ~ $ ~ $ matticus22 08/16/17 11:24:16 PM
#2511   $IDXG $IDXG $0 debt is all you need to matticus22 08/16/17 11:21:58 PM
#2510   $IDXG $IDXG low float ~ debt free ~ technology matticus22 08/16/17 11:13:08 PM
#2509   now the stock has it all: Camelot 08/16/17 10:09:41 PM
#2508   would love to see the $2 dollar break Camelot 08/16/17 10:07:52 PM
#2507   Will see a big spike tomorrow. Letsgogreen 08/16/17 09:50:44 PM
PostSubject